Document is current
Any future updates will be listed below
-
Authors
Senesi, Matteo
Lewis, Victoria
Adlard, Paul A.
Finkelstein, David I.
Kim, Jee Hyun
Collins, Steven J.
-
Funding
Funding for this research was provided by:
University of Melbourne
CJD Support Group Network
Australian Research Council
National Health and Medical Research Council (APP1083309, APP1105784)
- License Information
-
More Information
Article History
Received: 30 July 2025
Accepted: 29 October 2025
First Online: 19 November 2025
Declarations
:
: All the experiments were conducted in accordance with animal ethics approved by the University of Melbourne Animal Ethics Committee (AEC).
: PA is a senior scientific consultant to Alterity Therapeutics and the Chief Scientific Officer to Tessara Therapeutics. Neither company conducts activities that are relevant to the content of this manuscript, nor did they have any involvement in the work. SC has received payments from AbbVie, Biogen, Clarivate, Eisai and Lilly for educational and/or consulting services. None of the other authors has competing interests to declare.
